DCC sells InfoTech business for £100m as part of group simplification

DCC Plc has agreed to divest its UK and Ireland InfoTech business to private equity firm AURELIUS for an enterprise value of approximately £100 million, a strategic move aimed at simplifying its group structure. Despite generating £2 billion in revenue, InfoTech operated near break-even and contributed less than 10% of the Technology division's EBITA, with net cash proceeds from the sale deemed "not material" due to working capital. This divestment, following a prior Health division sale, positions DCC to focus on higher-value, more profitable segments, with further sales of its North American technology units anticipated in 2026.

Analysis

DCC Plc is executing a strategic simplification by divesting its UK and Ireland InfoTech business to AURELIUS for an enterprise value of approximately £100 million. While the unit generated substantial revenue of £2 billion, representing half of the Technology division's total, its financial contribution was minimal, operating near break-even and accounting for less than 10% of the division's EBITA. The transaction's financial impact is further muted, with net cash proceeds deemed "not material" due to significant working capital and supply chain financing liabilities of £156 million. This divestment follows the sale of the Health division and effectively sheds a "structurally challenged" asset, allowing DCC to focus on its higher-margin North American technology businesses. These retained operations generate a comparable £2 billion in revenue but a much healthier £75 million in EBITA, highlighting the strategic pivot towards more profitable segments. The group plans to complete its technology divestment program with the sale of its ProTech and LifeTech businesses, expected in calendar year 2026.

Key Decisions for Investors

• Investors should view this divestment as a strategic positive, focusing on the improved margin profile of the remaining group rather than the reduction in headline revenue.
• It is critical to look past the £100 million enterprise value, as the minimal net cash proceeds confirm this is a disposal of a low-quality, capital-intensive asset, which should de-risk the company's balance sheet and simplify operations.
• The planned sale of the remaining ProTech and LifeTech businesses in 2026 represents a key future catalyst; the valuation and terms of these future disposals will be crucial indicators of the restructuring's success.
• Monitor the performance of the retained, higher-margin North American technology assets, as their ability to drive profitability will be central to the investment thesis moving forward.